COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Loading content

Louise Crathorne

Postgraduate Research Health Economics

 01392 72 2282

 South Cloisters 1.06

 

South Cloisters, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

Overview

Louise’s background is in health technology assessment and evidence synthesis. Her interests have spread to health economics, having developed and critique a number of assessments to inform national decision-making for the National Institute for Health and Care Excellence (NICE), and locally for North East and West (NEW) Devon CCG, conducting rapid reviews as well as conducting budget impact analyses. Louise also has experience as a Senior Systematic Reviewer with the National Guidelines Alliance (Royal College of Obstetricians and Gynaecologists), contributing to the development of a number of NICE clinical guidelines.

Louise also has experience as a scientific writer with clinical trials and regulatory writing experience for GSK Vaccines for the meningococcal and chronic obstructive pulmonary disease (COPD) platforms, and has held positions as Head of Medical Writing at leading international medical communications agencies in the UK and Europe. She has also been involved in the production of a wide range of global and regional medical education materials. These have included peer-reviewed publications; meeting, marketing and training materials as well as information for patients. In addition, she has led the preparation of health technology assessment submissions for NICE, Scottish Medicines Consortium (SMC), National Centre for Pharmacoeconomics (NCPE) (Ireland), the National Health Care Institute (Zorginstituut Nederland [ZIN]), and the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]).

Qualifications

  • BA (Hons) English Literature
  • MSc Health Economics and Health Policy (Merit)

Research

Research interests

  • Evidence synthesis and systematic review
  • Economic evaluation of health technologies
  • Health technology assessment

Broad research specialisms:

Research interests and activities involve the use of economics and health economics principles to improve decision making in the health setting, and across related areas.

Research projects

  • CEA in dementia and alzheimer’s disease

Grants/Funding:

Co-applicant:

  • Five-year contract from the National Institute for Health Research (NIHR) Health Technology Assessment Programme (NIHR: £3.5 million)
  • MRC Newton Fund grant. Collaboration with the Fundação Oswaldo Cruz Foundation (Fiocruz) in Rio de Janeiro. Evaluation of the clinical and cost-effectiveness of diagnostic and therapeutic interventions for the treatment of hepatitis C: (total awarded not known) (~2014/2015)
  • The best of the UK? A report on the value and future of UK databases in the health and social care fields: (£3,000) (year not known)
  • Pain relief for venous cannulation of adults in routine treatment settings: a systematic review (£15,000) (~2011/2012)

Publications

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Bond M, Crathorne L, Peters J, Coelho H, Haasova M, Cooper C, Milner Q, Shawyer V, Hyde C, Powell R, et al (In Press). First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review and network meta-analysis. BMC Anesthesiol, 16(1). Abstract.  Author URL.  Full text.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long H, Medina-Lara A, et al (In Press). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment Abstract.  Full text.
Long L, Briscoe S, Cooper C, Hyde C, Crathorne L (2015). What is the clinical effectiveness and cost-effectiveness of conservative interventions for tendinopathy? an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations. Health Technology Assessment, 19(8), 5-73. Abstract.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model.  Author URL.
Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C (2013). Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health, 16(2), 288-296. Abstract.  Author URL.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C (2013). The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess, 17(14), 1-237. Abstract.  Author URL.  Full text.
Long HL, Briscoe S, Cooper C, Hyde C, Crathrone L (2013). What is the effectiveness and cost-effectiveness of conservative interventions for tendinopathy: an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations.
Crathorne L, Bond M, Cooper C, Elston J, Weiner G, Taylor R, Stein K (2012). A systematic review of the effectiveness and cost-effectiveness of bilateral multichannel cochlear implants in adults with severe-to-profound hearing loss. Clin Otolaryngol, 37(5), 342-354. Abstract.  Author URL.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technology Assessment, 16, 1-278. Abstract.  Author URL.
Cooper C, O'Mara-Eves A, Rogers M, Bethel A, Lowe J, Crathorne L, Gomersall A (2012). The best of the UK? a report on the value and future of UK databases in the health and social care fields: a systematic map protocol. BMJ Open, 2(3). Abstract.  Author URL.
Hoyle M, Crathorne L, Garside R, Hyde C (2011). Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess, 15 Suppl 1, 61-67. Abstract.  Author URL.
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2010). Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. Health Technol Assess, 14(Suppl. 2), 41-46. Abstract.  Author URL.
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2010). Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. Health technology assessment (Winchester, England), 14(Suppl. 2), 41-46. Abstract.

Conferences

Haasova M, Jones-Hughes T, Peters J, Snowsill T, Coelho H, Crathorne L, Mujica Mota R, Varley-Campbell J, Huxley N, Moore J, et al (2016). Immunosuppressive therapy for renal transplantation in adults: a systematic review and network meta-analyses. Health Technology
Assessment international (HTAi). 10th - 14th May 2016. Abstract.
Huxley N, Snowsill T, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mujica-Mota R, Napier M, et al (2014). A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA.  Author URL.
Bond M, Cooper C, Coelho H, Haasova M, Milner Q, Shawyer V, Hyde C, Powell R, Crathorne L (2014). First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review. WHO 22nd International HPH Conference.
Snowsill T, Huxley N, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mota MR, Napier M, et al (2014). MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS.  Author URL.
Huxley N, Haasova M, Crathorne L, Hyde C (2014). WHAT IS THE CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ERYTHROPOIETIN-STIMULATING AGENTS FOR THE TREATMENT OF PATIENTS WITH CANCER-TREATMENT INDUCED ANAEMIA? INSIGHTS FROM CUMULATIVE META-ANALYSES (CMA) AND LESSONS FOR COST-EFFECTIVENESS ANALYSES.  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR 1ST-LINE CHRONIC MYELOID LEUKAEMIA.  Author URL.

Reports

Haasova M, snowsill T, jones-hughes T, crathorne L, cooper C, varley-campbell J, mujica mota R, coelho H, huxley N, lowe J, et al (In Press). Immunosuppressive therapy for kidney transplantation in children and adolescents (review of technology appraisal 99); a systematic review and economic evaluation. , NIHR Health Technology Assessment Programme. Abstract.
Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle MW, et al (2015). Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer. MTA for NICE. Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2015). Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85). MTA for NICE. Author URL.
Crathorne L, Cooper C, Coelho H, Haasova M, Milner Q, Shawyer V, Hyde C, Bond M (2013). Pain relief for peripheral venous cannulation of adults in routine treatment settings: a systematic review. Royal Devon and Exeter Foundation Trust Hospital,  Exeter, University of Exeter.
Hoyle M, Crathorne L, Moxham T, Garside R, Hyde C (2010). Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Submitted to NICE as STA report.  Author URL.
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2009). Everolimus for the second-line treatment of advanced and/or metastatic renal cell carcinoma. NIHR HTA, NICE.

Publications by year


In Press

Bond M, Crathorne L, Peters J, Coelho H, Haasova M, Cooper C, Milner Q, Shawyer V, Hyde C, Powell R, et al (In Press). First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review and network meta-analysis. BMC Anesthesiol, 16(1). Abstract.  Author URL.  Full text.
Haasova M, snowsill T, jones-hughes T, crathorne L, cooper C, varley-campbell J, mujica mota R, coelho H, huxley N, lowe J, et al (In Press). Immunosuppressive therapy for kidney transplantation in children and adolescents (review of technology appraisal 99); a systematic review and economic evaluation. , NIHR Health Technology Assessment Programme. Abstract.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long H, Medina-Lara A, et al (In Press). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model. Health Technology Assessment Abstract.  Full text.

2016

Haasova M, Jones-Hughes T, Peters J, Snowsill T, Coelho H, Crathorne L, Mujica Mota R, Varley-Campbell J, Huxley N, Moore J, et al (2016). Immunosuppressive therapy for renal transplantation in adults: a systematic review and network meta-analyses. Health Technology
Assessment international (HTAi). 10th - 14th May 2016. Abstract.

2015

Huxley N, Crathorne L, Varley-Campbell J, Tikhonova I, Snowsill T, Briscoe S, Peters J, Bond M, Napier M, Hoyle MW, et al (2015). Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer. MTA for NICE. Author URL.
Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, et al (2015). Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85). MTA for NICE. Author URL.
Long L, Briscoe S, Cooper C, Hyde C, Crathorne L (2015). What is the clinical effectiveness and cost-effectiveness of conservative interventions for tendinopathy? an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations. Health Technology Assessment, 19(8), 5-73. Abstract.

2014

Huxley N, Snowsill T, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mujica-Mota R, Napier M, et al (2014). A COST-EFFECTIVENESS ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR TREATING CANCER-TREATMENT INDUCED ANAEMIA.  Author URL.
Bond M, Cooper C, Coelho H, Haasova M, Milner Q, Shawyer V, Hyde C, Powell R, Crathorne L (2014). First do no harm: pain relief for the peripheral venous cannulation of adults, a systematic review. WHO 22nd International HPH Conference.
Snowsill T, Huxley N, Hoyle M, Crathorne L, Haasova M, Briscoe S, Coelho H, Medina-Lara A, Mota MR, Napier M, et al (2014). MODEL-BASED COST-UTILITY ANALYSIS OF ERYTHROPOIESIS-STIMULATING AGENTS FOR THE TREATMENT OF CANCER-TREATMENT INDUCED ANAEMIA IN THE UK NHS.  Author URL.
Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, Briscoe S, Coelho H, Long L, Medina-Lara A, et al (2014). The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142): a systematic review and economic model.  Author URL.
Huxley N, Haasova M, Crathorne L, Hyde C (2014). WHAT IS THE CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF ERYTHROPOIETIN-STIMULATING AGENTS FOR THE TREATMENT OF PATIENTS WITH CANCER-TREATMENT INDUCED ANAEMIA? INSIGHTS FROM CUMULATIVE META-ANALYSES (CMA) AND LESSONS FOR COST-EFFECTIVENESS ANALYSES.  Author URL.

2013

Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C (2013). Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. Value Health, 16(2), 288-296. Abstract.  Author URL.
Crathorne L, Cooper C, Coelho H, Haasova M, Milner Q, Shawyer V, Hyde C, Bond M (2013). Pain relief for peripheral venous cannulation of adults in routine treatment settings: a systematic review. Royal Devon and Exeter Foundation Trust Hospital,  Exeter, University of Exeter.
Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P, Hyde C (2013). The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess, 17(14), 1-237. Abstract.  Author URL.  Full text.
Long HL, Briscoe S, Cooper C, Hyde C, Crathrone L (2013). What is the effectiveness and cost-effectiveness of conservative interventions for tendinopathy: an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations.

2012

Crathorne L, Bond M, Cooper C, Elston J, Weiner G, Taylor R, Stein K (2012). A systematic review of the effectiveness and cost-effectiveness of bilateral multichannel cochlear implants in adults with severe-to-profound hearing loss. Clin Otolaryngol, 37(5), 342-354. Abstract.  Author URL.
Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: Systematic reviews and economic analyses. Health Technology Assessment, 16, 1-278. Abstract.  Author URL.
Hoyle M, Pavey T, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, et al (2012). GENERAL METHODOLOGICAL ISSUES IN COST-EFFECTIVENESS ANALYSIS INSPIRED BY THE ASSESSMENT OF DASATINIB, NILOTINIB AND IMATINIB FOR 1ST-LINE CHRONIC MYELOID LEUKAEMIA.  Author URL.
Cooper C, O'Mara-Eves A, Rogers M, Bethel A, Lowe J, Crathorne L, Gomersall A (2012). The best of the UK? a report on the value and future of UK databases in the health and social care fields: a systematic map protocol. BMJ Open, 2(3). Abstract.  Author URL.

2011

Hoyle M, Crathorne L, Garside R, Hyde C (2011). Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technol Assess, 15 Suppl 1, 61-67. Abstract.  Author URL.

2010

Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2010). Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. Health Technol Assess, 14(Suppl. 2), 41-46. Abstract.  Author URL.
Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2010). Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis. Health technology assessment (Winchester, England), 14(Suppl. 2), 41-46. Abstract.
Hoyle M, Crathorne L, Moxham T, Garside R, Hyde C (2010). Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Submitted to NICE as STA report.  Author URL.

2009

Pitt M, Crathorne L, Moxham T, Bond M, Hyde C (2009). Everolimus for the second-line treatment of advanced and/or metastatic renal cell carcinoma. NIHR HTA, NICE.

Refresh publications

External Engagement and Impact

Committee/panel activities

  • National Institute for Health and Care Excellence Early Scientific Advice
  • National Institute for Health and Care Excellence Clinical Guidelines ad hoc committee member

Teaching

Teaching responsibilities: (Undergraduate, Postgraduate)

  • External:
    • British Association of Pharmaceutical Physicians (BrAPP) PostGraduate Course in Pharmaceutical Medicine Module (The Economics of Healthcare): Introduction to Health Economics and Health Technology Assessment (2017, 2018, and May 2019).

Supervision / Group

Back | Edit Profile